EGFR-driven up-regulation of decoy receptor 3 in keratinocytes contributes to the pathogenesis of psoriasis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 10, 2013, Pages 1538-1548

  Wu, Nan Lin ^a,b,c   Huang, Duen Yi ^a   Hsieh, Shie Liang ^d   Hsiao, Cheng Hsiang ^e   Lee, Te An ^b   Lin, Wan Wan ^a,f  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Decoy receptor 3; EGFR; Keratinocyte; NF B; Psoriasis; TNF

Indexed keywords

DECOY RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; BLOOD VESSEL; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMIS; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

DECOY RECEPTOR 3; EGFR; KERATINOCYTE; NF-ΚB; PSORIASIS; TNF-Α;

CELLS, CULTURED; HUMANS; KERATINOCYTES; NF-KAPPA B; PSORIASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84879585806     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.05.020     Document Type: Article

References (56)

1. Gottlieb A.B. Psoriasis: emerging therapeutic strategies. Nat. Rev. Drug Discov. 2005, 4:19-34.
2. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N. Engl. J. Med. 2009, 361:496-509.
3. Khan S. Psoriasis. N. Engl. J. Med. 2005, 353:848-850.(author reply 848-850.)
4. Elder J.T., Bruce A.T., Gudjonsson J.E., Johnston A., Stuart P.E., Tejasvi T., Voorhees J.J., Abecasis G.R., Nair R.P. Molecular dissection of psoriasis: integrating genetics and biology. J. Invest. Dermatol. 2010, 130:1213-1226.
5. Nickoloff B.J. Cracking the cytokine code in psoriasis. Nat. Med. 2007, 13:242-244.
6. Di Cesare A., Di Meglio P., Nestle F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J. Invest. Dermatol. 2009, 129:1339-1350.
7. Menter A., Korman N.J., Elmets C.A., Feldman S.R., Gelfand J.M., Gordon K.B., Gottlieb A., Koo J.Y., Lebwohl M., Leonardi C.L., Lim H.W., Van Voorhees A.S., Beutner K.R., Ryan C., Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J. Am. Acad. Dermatol. 2011, 65:137-174.
8. Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 2007, 445:866-873.
9. Shepard H.M., Brdlik C.M., Schreiber H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J. Clin. Invest. 2008, 118:3574-3581.
10. Stoll S.W., Kansra S., Peshick S., Fry D.W., Leopold W.R., Wiesen J.F., Sibilia M., Zhang T., Werb Z., Derynck R., Wagner E.F., Elder J.T. Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes. Neoplasia 2001, 3:339-350.
11. Pastore S., Mascia F., Mariani V., Girolomoni G. The epidermal growth factor receptor system in skin repair and inflammation. J. Invest. Dermatol. 2008, 128:1365-1374.
12. Shirakata Y., Komurasaki T., Toyoda H., Hanakawa Y., Yamasaki K., Tokumaru S., Sayama K., Hashimoto K. Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes. J. Biol. Chem. 2000, 275:5748-5753.
13. Elder J.T., Fisher G.J., Lindquist P.B., Bennett G.L., Pittelkow M.R., Coffey R.J., Ellingsworth L., Derynck R., Voorhees J.J. Overexpression of transforming growth factor alpha in psoriatic epidermis. Science 1989, 243:811-814.
14. Cook P.W., Piepkorn M., Clegg C.H., Plowman G.D., DeMay J.M., Brown J.R., Pittelkow M.R. Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J. Clin. Invest. 1997, 100:2286-2294.
15. Nanney L.B., Stoscheck C.M., Magid M., King L.E. Altered [125I]epidermal growth factor binding and receptor distribution in psoriasis. J. Invest. Dermatol. 1986, 86:260-265.
16. Higashiyama M., Hashimoto K., Matsumoto K., Yoshikawa K. Differential expression of transforming growth factor-alpha (TGF-alpha) and EGF receptor in transitional area of psoriatic epidermis. J. Dermatol. Sci. 1994, 7:45-53.
17. Boisseau-Garsaud A.M., Donatien P., Margerin C., Taieb A. EGF receptor expression and growth of psoriatic and normal human keratinocytes are modulated by 1.25 (OH)2-vitamin D3 ex vivo. Arch. Dermatol. Res. 1996, 288:453-457.
18. Lin W.W., Hsieh S.L. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem. Pharmacol. 2011, 81:838-847.
19. Pitti R.M., Marsters S.A., Lawrence D.A., Roy M., Kischkel F.C., Dowd P., Huang A., Donahue C.J., Sherwood S.W., Baldwin D.T., Godowski P.J., Wood W.I., Gurney A.L., Hillan K.J., Cohen R.L., Goddard A.D., Botstein D., Ashkenazi A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998, 396:699-703.
20. Hsu T.L., Chang Y.C., Chen S.J., Liu Y.J., Chiu A.W., Chio C.C., Chen L., Hsieh S.L. Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J. Immunol. 2002, 168:4846-4853.
21. Chang Y.C., Hsu T.L., Lin H.H., Chio C.C., Chiu A.W., Chen N.J., Lin C.H., Hsieh S.L. Modulation of macrophage differentiation and activation by decoy receptor 3. J. Leukoc. Biol. 2004, 75:486-494.
22. Chang Y.C., Chen T.C., Lee C.T., Yang C.Y., Wang H.W., Wang C.C., Hsieh S.L. Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood 2008, 111:5054-5063.
23. Yang C.R., Wang J.H., Hsieh S.L., Wang S.M., Hsu T.L., Lin W.W. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. Cell Death Differ. 2004, 11(Suppl. 1):S97-107.
24. Hsu M.J., Lin W.W., Tsao W.C., Chang Y.C., Hsu T.L., Chiu A.W., Chio C.C., Hsieh S.L. Enhanced adhesion of monocytes via reverse signaling triggered by decoy receptor 3. Exp. Cell Res. 2004, 292:241-251.
25. Otsuki T., Tomokuni A., Sakaguchi H., Aikoh T., Matsuki T., Isozaki Y., Hyodoh F., Ueki H., Kusaka M., Kita S., Ueki A. Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients. Clin. Exp. Immunol. 2000, 119:323-327.
26. Funke B., Autschbach F., Kim S., Lasitschka F., Strauch U., Rogler G., Gdynia G., Li L., Gretz N., Macher-Goeppinger S., Sido B., Schirmacher P., Meuer S.C., Roth W. Functional characterisation of decoy receptor 3 in Crohn's disease. Gut 2009, 58:483-491.
27. Lee C.S., Hu C.Y., Tsai H.F., Wu C.S., Hsieh S.L., Liu L.C., Hsu P.N. Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus. Clin. Exp. Immunol. 2008, 151:383-390.
28. Hayashi S., Miura Y., Nishiyama T., Mitani M., Tateishi K., Sakai Y., Hashiramoto A., Kurosaka M., Shiozawa S., Doita M. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum. 2007, 56:1067-1075.
29. Chen C.Y., Yang K.Y., Chen M.Y., Chen H.Y., Lin M.T., Lee Y.C., Perng R.P., Hsieh S.L., Yang P.C., Chou T.Y. Decoy receptor 3 levels in peripheral blood predict outcomes of acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 2009, 180:751-760.
30. Maeda T., Hao C., Tron V.A. Ultraviolet light (UV) regulation of the TNF family decoy receptors DcR2 and DcR3 in human keratinocytes. J. Cutan. Med. Surg. 2001, 5:294-298.
31. Chen C.C., Yang Y.H., Lin Y.T., Hsieh S.L., Chiang B.L. Soluble decoy receptor 3: increased levels in atopic patients. J. Allergy Clin. Immunol. 2004, 114:195-197.
32. Bamias G., Evangelou K., Vergou T., Tsimaratou K., Kaltsa G., Antoniou C., Kotsinas A., Kim S., Gorgoulis V., Stratigos A.J., Sfikakis P.P. Upregulation and nuclear localization of TNF-like cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions. Exp. Dermatol. 2011, 20:725-731.
33. Yang C.R., Hsieh S.L., Teng C.M., Ho F.M., Su W.L., Lin W.W. Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res. 2004, 64:1122-1129.
34. Yang C.R., Hsieh S.L., Ho F.M., Lin W.W. Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-kappa B-dependent up-regulation of intercellular adhesion molecule-1, VCAM-1, and IL-8 expression. J. Immunol. 2005, 174:1647-1656.
35. Hsiao C.H., Lin Y.T., Lai C.C., Hsueh P.R. Clinicopathologic characteristics of nontuberculous mycobacterial lung disease in Taiwan. Diagn. Microbiol. Infect. Dis. 2010, 68:228-235.
36. Wu N.L., Lee T.A., Tsai T.L., Lin W.W. TRAIL-induced keratinocyte differentiation requires caspase activation and p63 expression. J. Invest. Dermatol. 2011, 131:874-883.
37. Neurath M.F. IL-23: a master regulator in Crohn disease. Nat. Med. 2007, 13:26-28.
38. Ellinghaus D., Ellinghaus E., Nair R.P., Stuart P.E., Esko T., Metspalu A., Debrus S., Raelson J.V., Tejasvi T., Belouchi M., West S.L., Barker J.N., Koks S., Kingo K., Balschun T., Palmieri O., Annese V., Gieger C., Wichmann H.E., Kabesch M., Trembath R.C., Mathew C.G., Abecasis G.R., Weidinger S., Nikolaus S., Schreiber S., Elder J.T., Weichenthal M., Nothnagel M., Franke A. Combined analysis of genome-wide association studies for crohn disease and psoriasis identifies seven shared susceptibility loci. Am. J. Hum. Genet. 2012, 90:636-647.
39. Bamias G., Siakavellas S.I., Stamatelopoulos K.S., Chryssochoou E., Papamichael C., Sfikakis P.P. Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. Clin. Immunol. 2008, 129:249-255.
40. Wu Y., Han B., Sheng H., Lin M., Moore P.A., Zhang J., Wu J. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int. J. Cancer 2003, 105:724-732.
41. Han B., Bojalil R., Amezcua-Guerra L.M., Springall R., Valderrama-Carvajal H., Wu J., Luo H. DcR3 as a diagnostic parameter and risk factor for systemic lupus erythematosus. Int. Immunol. 2008, 20:1067-1075.
42. Hsu T.L., Wu Y.Y., Chang Y.C., Yang C.Y., Lai M.Z., Su W.B., Hsieh S.L. Attenuation of Th1 response in decoy receptor 3 transgenic mice. J. Immunol. 2005, 175:5135-5145.
43. Chen S.J., Wang Y.L., Kao J.H., Wu S.F., Lo W.T., Wu C.C., Tao P.L., Wang C.C., Chang D.M., Sytwu H.K. Decoy receptor 3 ameliorates experimental autoimmune encephalomyelitis by directly counteracting local inflammation and downregulating Th17 cells. Mol. Immunol. 2009, 47:567-574.
44. Wang Y.L., Chou F.C., Sung H.H., Fan P.L., Hsueh C.W., Lin W.C., Chen S.J., Lin W.W., Sytwu H.K. Decoy receptor 3 protects non-obese diabetic mice from autoimmune diabetes by regulating dendritic cell maturation and function. Mol. Immunol. 2010, 47:2552-2562.
45. Sarra M., Pallone F., Macdonald T.T., Monteleone G. IL-23/IL-17 axis in IBD. Inflamm. Bowel Dis. 2010, 16:1808-1813.
46. Arican O., Aral M., Sasmaz S., Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005, 2005:273-279.
47. Abdel-Hamid M.F., Aly D.G., Saad N.E., Emam H.M., Ayoub D.F. Serum levels of interleukin-8, tumor necrosis factor-alpha and gamma-interferon in Egyptian psoriatic patients and correlation with disease severity. J. Dermatol. 2011, 38:442-446.
48. Strasser A., Jost P.J., Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009, 30:180-192.
49. Kakiashvili E., Dan Q., Vandermeer M., Zhang Y., Waheed F., Pham M., Szaszi K. The epidermal growth factor receptor mediates tumor necrosis factor-alpha-induced activation of the ERK/GEF-H1/RhoA pathway in tubular epithelium. J. Biol. Chem. 2011, 286:9268-9279.
50. Hobbs S.S., Goettel J.A., Liang D., Yan F., Edelblum K.L., Frey M.R., Mullane M.T., Polk D.B. TNF transactivation of EGFR stimulates cytoprotective COX-2 expression in gastrointestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 301:G220-229.
51. Schmiegel W., Roeder C., Schmielau J., Rodeck U., Kalthoff H. Tumor necrosis factor alpha induces the expression of transforming growth factor alpha and the epidermal growth factor receptor in human pancreatic cancer cells. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:863-867.
52. Ziv E., Rotem C., Miodovnik M., Ravid A., Koren R. Two modes of ERK activation by TNF in keratinocytes: different cellular outcomes and bi-directional modulation by vitamin D. J. Cell. Biochem. 2008, 104:606-619.
53. Chen P.H., Yang C.R. Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway. J. Immunol. 2008, 181:8441-8449.
54. Kim S., Fotiadu A., Kotoula V. Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia. Clin. Immunol. 2005, 115:286-294.
55. Le Page C., Koumakpayi I.H., Lessard L., Saad F., Mes-Masson A.M. Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2-mediated constitutive NF-kappaB activation in prostate cancer cells. Prostate 2005, 65:306-315.
56. Biswas D.K., Dai S.C., Cruz A., Weiser B., Graner E., Pardee A.B. The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10386-10391.